Metrics to compare | PTGP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTGPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.2x | −6.8x | −0.4x | |
PEG Ratio | −1.03 | 0.04 | 0.00 | |
Price/Book | 2.6x | 3.0x | 2.6x | |
Price / LTM Sales | 525.1x | 4.2x | 3.0x | |
Upside (Analyst Target) | 216.0% | 63.7% | 58.0% | |
Fair Value Upside | Unlock | 9.5% | 8.0% | Unlock |
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in preclinical trial to treat T1D. The company also develops CD6/CTLA4 CAR-Treg which is in phase I clinical trial to treat stage 3 T1D; CD6/CTLA4 CAR-Treg which is in preclinical trial for the treatment of vitiligo, atopic derm, psoriasis, and alopecia areata; CD6/CTLA4 CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and PTG-OO7 + Rituximab which is in preclinical trial to treat presympt T1D. In addition, it is developing cell therapies involve the use of human cells to regenerate a patient’s damaged tissues or organs. The company was founded in 2015 and is headquartered in Gdansk, Poland.